Awarded further Bicycle Therapeutics contract

6 April 2020

Physiomics plc

("Physiomics") or (the "Company")

Physiomics awarded further contract by Bicycle Therapeutics

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract of undisclosed value by its existing client, Bicycle Therapeutics ("Bicycle") (the "Project").

The Project is an extension of the work the Company completed on Bicycle's lead programme, BT1718 (currently in a Cancer Research UK-sponsored Phase I/IIa study), which Physiomics announced on 8 July 2019.  Physiomics' role is related to the analysis of clinical data from this trial and its work on the initial project was acknowledged in a poster presentation, at the ESMO conference, in September 2019⁽¹⁾.  The Project is expected to be completed in the next six months.

Dr Jim Millen, CEO said: "We are delighted to continue to expand our relationship with Bicycle Therapeutics, which is rapidly becoming a key high-profile client.  It's also pleasing that we are able to sign new business in the current environment and hope to see this continue over the course of the rest of this calendar year."

(1)https://www.bicycletherapeutics.com/wp-content/uploads/ESMO-Sep-2019-FINAL.pdf

Enquiries:

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0) 20 7409 3494

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.